Cantor Fitzgerald Raises Earnings Estimates for Arvinas

Arvinas, Inc. (NASDAQ:ARVN) – Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($2.71) per share for the year, up from their prior estimate of ($6.11). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the prior year, the firm posted ($2.53) earnings per share.

ARVN has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $81.00 price target on shares of Arvinas in a research report on Tuesday, March 11th. Oppenheimer lowered Arvinas from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 11th. BTIG Research began coverage on Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price for the company. Barclays cut their price target on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Finally, Wells Fargo & Company set a $26.00 price objective on shares of Arvinas and gave the company an “overweight” rating in a research note on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.47.

Arvinas Stock Down 2.8 %

ARVN opened at $8.75 on Thursday. Arvinas has a twelve month low of $7.91 and a twelve month high of $43.07. The company has a fifty day moving average of $16.24 and a 200-day moving average of $21.29. The stock has a market cap of $601.76 million, a PE ratio of -3.16 and a beta of 1.95.

Insider Buying and Selling

In related news, CEO John G. Houston sold 31,338 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock worth $769,402 in the last quarter. Insiders own 5.23% of the company’s stock.

Institutional Trading of Arvinas

Several institutional investors and hedge funds have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. purchased a new position in Arvinas during the fourth quarter worth about $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Arvinas by 0.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after buying an additional 3,047 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in shares of Arvinas in the 4th quarter worth approximately $749,000. Woodline Partners LP grew its holdings in shares of Arvinas by 39.2% in the fourth quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock valued at $13,280,000 after acquiring an additional 194,996 shares in the last quarter. Finally, Twinbeech Capital LP purchased a new stake in shares of Arvinas during the fourth quarter valued at approximately $3,146,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.